Table 1.
Characterization of the study population at baseline.
| Chronic kidney disease (n = 36) | Control (n = 20) | p value | |
| Clinical and demographic characteristics | |||
| Age, mean±SD | 53.17±12.00 | 43.4±0 11.00 | 0.06 |
| Male gender, n (%) | 23 (63) | 9 (45) | 0.17 |
| White race, n (%) | 23 (63.9) | 13 (65) | 0.97 |
| Black race, n (%) | 7(19.4) | 4 (20) | 0.98 |
| Diabetes mellitus, n (%) | 10 (27) | --- | --- |
| BMI (kg/m2), mean±SD | 26.53±4.95 | 26.88±5.10 | 0.8 |
| BP systolic (mm Hg), mean±SD | 143.63±17.80 | 131.16±18.20 | 0.01* |
| BP diastolic (mm Hg), mean±SD | 86.11±9.87 | 81.0±11.34 | 0.08 |
| Serum albumin (g/dL), mean±SD | 4.27±0.34 | 4.37±0.22 | 0.25 |
| Serum creatinine (mg/dL), mean±SD | 2.39±1.11 | 0.77±0.21 | 0.001* |
| eGFR (mL/min/1.73 m2), mean±SD | 34.27±16.02 | 107.60±26.73 | 0.001* |
| CKD stage | |||
| 3 n (%) | 21 (58.30) | --- | --- |
| 4 n (%) | 12 (33.30) | --- | --- |
| 5 n (%) | 3 (8.30) | --- | --- |
| Biochemical characteristics | |||
| Prohepcidin (ng/mL) mean±SD | 166.24±55.70 | 147.39±51.50 | 0.22 |
| IL-6 (pg/mL) mean±SD | 4.04±2.40 | 2.95±2.20 | 0.04* |
| us-CRP (mg/L) mean±SD | 6.18±5.39 | 3.04±3.82 | 0.03* |
| Hemoglobin (g/dL) mean±SD | 12.72±1.96 | 13.30±1.89 | 0.29 |
| Ferritin (ng/dL) mean±SD | 180.60±129.0 | 184.0±154.0 | 0.93 |
| TSat (%) | 29.30 | 33.90 | 0.01* |
*p<0.05.
SD = standard deviation; n = number; BMI = body mass index; BP = blood pressure; eGFR = estimated glomerular filtration rate; CKD = chronic kidney disease; IL-6 = interleukin-6; us-CRP = ultrasensitive C-reactive protein; TSat = transferrin saturation.